A Clinical Evaluation of the RheOx Bronchial Rheoplasty System

Launched by ENERGENX MEDICAL LTD. · Nov 29, 2022

Keywords

ClinConnect Summary

This clinical trial is looking into a new treatment called the RheOx Bronchial Rheoplasty System for patients suffering from chronic bronchitis, a condition that often affects people with moderate to severe Chronic Obstructive Pulmonary Disease (COPD). The goal of the study is to see how well this system works in relieving symptoms like a persistent cough and difficulty breathing. Researchers are currently recruiting participants aged 35 to 80 who have been diagnosed with chronic bronchitis and have tried other medications without sufficient relief. To be eligible, participants should have a specific level of breathing difficulty, as measured by questionnaires and lung function tests.

If you decide to participate, you will undergo two bronchoscopies, which are procedures that allow doctors to look inside your lungs, and you will be monitored closely throughout the trial. It's important to note that certain health conditions, such as severe lung diseases or recent infections, may prevent you from joining. Overall, this trial aims to provide valuable insights into a potential new treatment for chronic bronchitis, which could help improve the quality of life for many patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Subject's age is ≥35 years and ≤80 years
• • 2. Subject has chronic bronchitis, defined as productive cough for three months in each of two successive years, whereas other causes of productive cough have been ruled out.
• • 3. Subject has a CAT score ≥ 10.
• • 4. Subject's responses to the first two questions of the CAT questionnaire sum to ≥ 7 points or the sum is 6 points and the subject's total CAT score is \> 20 points.
• • 5. Subject has a SGRQ score ≥ 25.
• • 6. Subject has post -bronchodilator FEV1/FVC \< 0.7.
• • 7. Subject has post-bronchodilator FEV1 percent predicted of ≥ 30%.
• • 8. Subject is receiving guideline directed pharmacotherapy which includes one or more long-acting bronchodilator (LAMA, LABA) with or without an inhaled corticosteroid for at least 8 weeks prior to enrollment.
• • 9. Subject has a cigarette smoking history of at least ten pack years (packs per day x years of smoking), and has had quit smoking for at least 6 months before enrollment;
• • 10. In the opinion of the investigator, subject is able to undergo 2 bronchoscopies under general anesthesia and is able to adhere to the study follow-up schedule.
• • Subject has provided informed consent.
• Exclusion Criteria:
• • 1. Subject has known unresolved lower respiratory tract infection (e.g., pneumonia, mycobacterium avium-intracellulare infection (MAI), fungus, tuberculosis).
• • 2. Subject has a pulmonary nodule or cavity . In the judgement of the investigator, the subject may require intervention during the course of the study.
• • 3. Subject has clinically significant bronchiectasis influencing the subject's clinical symptoms of cough and phlegm.
• • 4. Subject has severe other lung diseases (including interstitial pneumonia, lung fibrosis, pulmonary fibrosis with emphysema, atelectasis, unresolved lung Cancer, giant pulmonary bullae);
• • 5. Subject has asthma based on Global Initiative for Asthma (GINA) criteria.
• • 6. Subject has had prior severe respiratory infection with SARS-CoV-2 (COVID-19) that required ICU support with non-invasive and/or invasive mechanical ventilation.
• • 7. Subject had prior lung surgery, such as lung transplant, LVRS, lobectomy, lung implant/prosthesis, metal airway stent, valves, coils or bullectomy. Prior pneumothorax without lung resection, pleural procedures without surgery, or segmentectomy are acceptable
• • 8. Subject has a history of arrhythmia within past two years which includes tachy-atrial arrhythmias, any ventricular tachy-arrhythmias, grade II, II or III AV transmission history of conduction blockor, sinus bradycardia with heart rate less than 45 beats per minute.
• • 9. Subject is on anticoagulation for cardiovascular indications and, at the discretion of the investigator, is unable to have anticoagulants (i.e., Aspirin, Plavix, Coumadin) withheld for the bronchoscopy procedure per institution's standard of care.
• • \* If the anticoagulants withheld is clinically acceptable, five to seven days withheld before enrollment is advised.
• • 10. Subject has other serious diseases (e.g. congestive heart failure, cardiomyopathy, or myocardial infarction in the past year, renal failure, liver failure, cerebrovascular accident within the past 6 months, uncontrolled diabetes (HbA1c \>8%), uncontrolled hypertension (diastolic BP \>100mmHg) or autoimmune disease requiring treatment with immunosuppressant medications or a disease requiring chemotherapy).
• • 11. Subject has uncontrolled gastroesophageal reflux disease（GERD）that indicated by the common symptoms and signs like stomach burning, acid reflux, regurgitation of partial digested food or acid into throat.
• • 12. Subject has any implantable electronic device (e.g., pacemaker, cardioverter defibrillator, neuro-stimulation devices).
• • 13. Subject has known airway colonization with resistant organisms, such as pseudomonas, methicillin-resistant Staphylococcus aureus (MRSA), Burkholderia cepacia complex, Mycobacterium Tuberculosis (MTB), Mycobacterium abscessus mucor or significant fungus.
• • 14. Subject has known severe pulmonary hypertension.
• • 15. Subject has a known sensitivity to medication required to perform bronchoscopy (i.e., lidocaine, atropine, benzodiazepines, Propofol).
• • 16. Subject has known allergy to nickel.
• • 17. Subject is receiving any traditional Chines herbs for cough or phlegm. \* mucolytics may be recommended by institute clinical practice, carbocysteine, oral or inhaled N-acetylcysteine, Eucalyptol and ambroxol hydrochloride are suggested.
• • \* The treatrment of this study is to ablate bronchial mucosa by airway intervention, then mucosa epithelium is repaired. The effect of inhalation on the repair of airway mucosal epithelium is unknown. Therefore, it is not recommended to oral or inhaled N-acetylcysteine during treatment and follow-up.
• • 18. Subject has a steroid-dependent condition requiring \>10 mg of oral corticosteroid (e.g. prednisone or equivalence.) per day.
• • 19. Subject is unable to walk over 225 meters in 6 minutes.
• • 20. Subject has emphysema of greater than or equal to 35% (low attenuation area≤ -950HU) as determined by HRCT quantitative analysis.
• • 21. Subject is pregnant, nursing, or planning to get pregnant during study duration.
• • 22. Subject has HIV infection or active syphilis infection;
• • 23. Subject is currently participating in another clinical study involving an investigational product.
• • 24. Subject is not suitable for bronchoscopy by the judgement of investigator.

Trial Officials